Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A. Platzbecker U, et al. Among authors: kiewe p. Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Lancet Oncol. 2017. PMID: 28870615 Clinical Trial.
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Platzbecker U, Götze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlägel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A. Platzbecker U, et al. Among authors: kiewe p. J Clin Oncol. 2022 Nov 20;40(33):3800-3807. doi: 10.1200/JCO.21.02476. Epub 2022 Aug 23. J Clin Oncol. 2022. PMID: 35998303 Free PMC article. Clinical Trial.
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).
Wermke M, Schuster C, Nolte F, Al-Ali HK, Kiewe P, Schönefeldt C, Jakob C, von Bonin M, Hentschel L, Klut IM, Ehninger G, Bornhäuser M, Baretton G, Germing U, Herbst R, Haase D, Hofmann WK, Platzbecker U. Wermke M, et al. Among authors: kiewe p. Br J Haematol. 2016 Dec;175(5):917-924. doi: 10.1111/bjh.14345. Epub 2016 Oct 7. Br J Haematol. 2016. PMID: 27714772 Free article. Clinical Trial.
Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany.
Braitsch K, Schmalbrock LK, Jung P, Bumeder I, Kiewe P, Hecker JS, Verbeek M, Westermann J, Bullinger L, Keller U, Bassermann F, Krönke J, Götze KS, Rieger K. Braitsch K, et al. Among authors: kiewe p. Hemasphere. 2022 Aug 9;6(9):e759. doi: 10.1097/HS9.0000000000000759. eCollection 2022 Sep. Hemasphere. 2022. PMID: 35966764 Free PMC article. No abstract available.
Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.
Sebastian M, Kiewe P, Schuette W, Brust D, Peschel C, Schneller F, Rühle KH, Nilius G, Ewert R, Lodziewski S, Passlick B, Sienel W, Wiewrodt R, Jäger M, Lindhofer H, Friccius-Quecke H, Schmittel A. Sebastian M, et al. Among authors: kiewe p. J Immunother. 2009 Feb-Mar;32(2):195-202. doi: 10.1097/CJI.0b013e318195b5bb. J Immunother. 2009. PMID: 19238019 Clinical Trial.
Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.
Reinwald M, Schleyer E, Kiewe P, Blau IW, Burmeister T, Pursche S, Neumann M, Notter M, Thiel E, Hofmann WK, Kolb HJ, Burdach S, Bender HU. Reinwald M, et al. Among authors: kiewe p. Biomed Res Int. 2014;2014:637059. doi: 10.1155/2014/637059. Epub 2014 Jun 15. Biomed Res Int. 2014. PMID: 25025064 Free PMC article. Clinical Trial.
Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma.
Korfel A, Schlegel U, Herrlinger U, Dreyling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T, Kebir S, Thiel E, Martus P, Kiewe P. Korfel A, et al. Among authors: kiewe p. J Clin Oncol. 2016 May 20;34(15):1757-63. doi: 10.1200/JCO.2015.64.9897. Epub 2016 Mar 14. J Clin Oncol. 2016. PMID: 26976424 Clinical Trial.
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Schmid P, Kühnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, Freier W, Kümmel S, Van de Velde H, Regierer A, Possinger K. Schmid P, et al. Among authors: kiewe p. Ann Oncol. 2008 May;19(5):871-6. doi: 10.1093/annonc/mdm569. Epub 2008 Jan 21. Ann Oncol. 2008. PMID: 18209010 Free article. Clinical Trial.
40 results